fda compounding semaglutide warning letters october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Compounded weight loss injections —

FDA-Approved Medication, Prescribed After Labs Compounded GLP-1s sold online are under active FDA enforcement

For storage beyond that, prepare single-use aliquots at -20C, where reconstituted peptide remains stable for up to 6 months

The glucagon receptor component of retatrutide's mechanism is of particular interest for liver health, as glucagon signalling is thought to play a role in hepatic fat metabolism, though the precise mechanisms in humans remain under investigation

Weight loss on a GLP-1 typically starts in the first month, picks up during dose escalation, and plateaus around 1214 months

Constipation: a compounding problem Postpartum constipation is already common

GLP-1 and its analogs have emerged as significant therapeutic agents for managing metabolic disorders